This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Milionis, H. J. Articles by Elisaf, M. S. Search for Related Content PubMed PubMed Citation Articles by Milionis, H. J. Articles by Elisaf, M. S. Social Bookmarking                         What's this?

Starting with Rosuvastatin in Primary Hyperlipidemia—

Is There More Than Lipid Lowering?

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece

Irene F. Gazi, MD

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece

Theodosios D. Filippatos, MD

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece

Vasilios Tzovaras, MD

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece

George Chasiotis, PhD

Laboratory of Biochemistry, University Hospital of Ioannina, Ioannina, Greece

John Goudevenos, MD

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece

Konstantine Seferiadis, PhD

Laboratory of Biochemistry, University Hospital of Ioannina, Ioannina, Greece

Moses S. Elisaf, MD, FRSH, FASA

Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece, hmilioni{at}cc.uoi.gr

The authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on several nonlipid metabolic variables, along with its safety and tolerability, in patients treated for primary hyperlipidemia. Patients (n=55) with primary hyperlipidemia were open-label assigned to the recommended starting dose of rosuvastatin 10 mg/day, and serum metabolic variables were measured at baseline and after 8 and 20 weeks. Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. The LDL-C treatment target was achieved in 71% of patients. No significant variations in renal function parameters (serum creatinine and creatinine clearance), insulin resistance estimates, and serum concentrations of uric acid, total homocysteine, vitamin B12, and folic acid were observed during the period of treatment. High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p<0.0001). In conclusion, rosuvastatin at 10 mg/day is a highly effective, safe, and well-tolerated monotherapy option for patients with primary hyperlipidemia, with a favorable antiinflammatory potential and nondeteriorating effects on renal function.

Angiology, Vol. 56, No. 5, 585-592 (2005)
DOI: 10.1177/000331970505600510


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf An Overview of the Extra-Lipid Effects of Rosuvastatin Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174. [Abstract] [PDF]

				M. S. Kostapanos, H. J. Milionis, I. Gazi, C. Kostara, E. T. Bairaktari, and M. Elisaf Rosuvastatin Increases {alpha}-1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia. J. Clin. Pharmacol., November 1, 2006; 46(11): 1337 - 1343. [Abstract] [Full Text] [PDF]